Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic DiseaseModifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

被引：0
|
作者：
Gottlieb, Alice [1 ]
Husni, Elaine [2 ]
Shuler, Catherine [3 ]
Burge, Russel [3 ]
Lin, Chen-Yen [3 ]
Lee, Chin [3 ]
Gladman, Dafna [4 ]
机构：
[1] New York Med Coll, Valhalla, NY 10595 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2017年 / 44卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
175
引用
收藏
页码：924 / 925
页数：2
相关论文
共 50 条
  • [41] IXEKIZUMAB IMPROVES PATIENT-REPORTED OUTCOMES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR-INHIBITORS
    Kavanaugh, A.
    Marzo-Ortega, H.
    Vender, R.
    Birt, J.
    Adams, D.
    Benichou, O.
    Lin, C-Y
    Nash, P.
    INTERNAL MEDICINE JOURNAL, 2018, 48 : 39 - 40
  • [42] Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors
    Kavanaugh, Arthur
    Marzo-Ortega, Helena
    Vender, Ronald
    Birt, Julie
    Adams, David
    Benichou, Olivier
    Lin, Chen-Yen
    Nash, Peter
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [43] A Randomized, Double-blind, Active-and Placebo-controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naive to Biologic Disease Modifying Antirheumatic Drugs with Active Psoriatic Arthritis
    Mease, Philip
    van der Heijde, Desiree
    Ritchlin, Christopher
    Cuchacovich, Raquel
    Shuler, Catherine
    Lin, Chen-Yen
    Vangerow, Harald
    Samanta, Suvajit
    Lee, Chin
    Gladman, Dafna
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1169 - 1169
  • [44] Similar Improvements in Physical Function, Quality of Life and Work Productivity Among Rheumatoid Arthritis Patients Treated with 2 Different Doses of Methotrexate in Combination with Adalimumab
    Kaeley, Gurjit S.
    Nishio, Midori Jane
    MacCarter, Daryl
    Griffith, Jenny
    Kupper, Hartmut
    Garg, Vishvas
    Kalabic, Jasmina
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1042 - S1043
  • [45] IMPAIRMENTS IN QUALITY OF LIFE, DAILY FUNCTION, AND WORK PRODUCTIVITY AND ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS WHO USE SUBCUTANEOUS BIOLOGIC THERAPIES
    Tang, B.
    Naim, A.
    McKenzie, R. S.
    Bailey, R.
    Freedman, D.
    Wagner, S.
    Piech, C. T.
    VALUE IN HEALTH, 2009, 12 (03) : A70 - A71
  • [46] A randomized, double-blind, active-and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease-modifying antirheumatic drugs with active psoriatic arthritis
    Mease, P. J.
    van der Heijde, D.
    Ritchlin, C. T.
    Cuchacovich, R. S.
    Shuler, C. L.
    Lin, C.
    Vangerow, H.
    Samanta, S.
    Lee, C. H.
    Gladman, D. D.
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (03) : E30 - E30
  • [47] USTEKINUMAB IMPROVES PHYSICAL FUNCTION, QUALITY OF LIFE AND WORK PRODUCTIVITY OF PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO WERE NAIVE TO MTX, DESPITE MTX THERAPY OR PREVIOUSLY TREATED WITH ANTI-TNFA: RESULTS FROM PSUMMIT I AND PSUMMIT II
    Rahman, P.
    Puig, L.
    Gottlieb, A. B.
    Kavanaugh, A.
    McInnes, I.
    Ritchlin, C.
    Li, S.
    Wang, Y.
    Zhao, N.
    Ganguly, R.
    Song, M.
    Han, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 671 - 672
  • [48] The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Jeffrey R. Curtis
    Iain B. McInnes
    Proton Rahman
    Dafna D. Gladman
    Steven Peterson
    Prasheen Agarwal
    Feifei Yang
    Alexa P. Kollmeier
    Elizabeth C. Hsia
    Natalie J. Shiff
    Bei Zhou
    Chenglong Han
    May Shawi
    William Tillett
    Philip J. Mease
    Advances in Therapy, 2022, 39 : 4613 - 4631
  • [49] DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100
    Kristensen, L. E.
    Soliman, A. M.
    Padilla, B.
    Papp, K.
    Ostor, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1123 - 1123
  • [50] SECUKINUMAB SIGNIFICANTLY IMPROVES PHYSICAL FUNCTION, QUALITY OF LIFE, FATIGUE AND WORK PRODUCTIVITY IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS TREATED FOR UP TO 52 WEEKS IN THE PHASE III MEASURE 2 STUDY
    Emery, Paul
    Deodhar, Atul
    Sieper, Joachim
    Andersson, Mats
    Richards, Hanno
    RHEUMATOLOGY, 2016, 55 : 35 - 35
12345